Please note that effective from 20 December 2022, changes are being made to the objective and policy of the Fund. For further information please contact the Manager, Monday to Friday between 9.00am to 5.00pm on 0370 050 0955 or by email at Investments@landg.com
As at 31 Oct 2022
FTSE World - Health Care Index
| Valuation frequency | Daily, 3pm (UK time) |
| Dealing frequency | Daily |
| Settlement period | T+4 |
Source: Lipper
As at 31 Oct 2022
| Cumulative | Fund | Benchmark |
| 1 month | 3.23 | 5.13 |
| 6 months | 4.39 | 6.66 |
| Year to date | 4.00 | 5.85 |
| 3 years | 41.93 | 46.60 |
| 5 years | 71.79 | 81.74 |
| Since launch | 347.20 | - |
| Annualised | Fund | Benchmark |
| 1 year | 10.15 | 10.47 |
| 3 years | 12.37 | 13.59 |
| 5 years | 11.42 | 12.68 |
| Since launch | 7.04 | - |
As at 30 Sep 2022
| Cumulative | Fund | Benchmark |
| Quarterly | 3.04 | 1.00 |
| Year to date | 0.74 | 0.69 |
| 3 years | 37.80 | 40.12 |
| 5 years | 67.00 | 72.75 |
| Since launch | 333.20 | - |
| Annualised | Fund | Benchmark |
| 1 year | 6.70 | 7.49 |
| 3 years | 11.27 | 11.89 |
| 5 years | 10.79 | 11.55 |
| Since launch | 6.91 | - |
| 12 months to 30 September | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Fund | 17.89 | 2.80 | 13.78 | 13.51 | 6.70 |
| Benchmark | 18.87 | 3.72 | 15.63 | 12.73 | 7.49 |
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Fund | 9.21 | 6.85 | 18.38 | 8.63 | 19.09 |
| Benchmark | 10.79 | 9.87 | 18.19 | 10.10 | 19.15 |
| 1 year | 3 years | 5 years | Since launch | |
|---|---|---|---|---|
| Fund | 10.15 | 12.37 | 11.42 | 7.04 |
| Benchmark | 10.47 | 13.59 | 12.68 | - |
| 1 year | 3 years | 5 years | Since launch | |
|---|---|---|---|---|
| Fund | 6.70 | 11.27 | 10.79 | 6.91 |
| Benchmark | 7.49 | 11.89 | 11.55 | - |
Performance for the C Acc unit class in GBP, launched on 22 February 2019. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.
Past performance is not a guide to the future.
Performance for the C Inc unit class in GBP, launched on 22 February 2019. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.
Past performance is not a guide to the future.
Performance for the F Acc unit class in GBP, launched on 20 December 2012. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.
Past performance is not a guide to the future.
Performance for the F Inc unit class in GBP, launched on 20 December 2012. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.
Past performance is not a guide to the future.
Performance for the I Acc unit class in GBP, launched on 26 August 2005. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.
Past performance is not a guide to the future.
Performance for the I Inc unit class in GBP, launched on 26 August 2005. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.
Past performance is not a guide to the future.
Performance for the R Acc unit class in GBP, launched on 01 November 2000. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.
Past performance is not a guide to the future.
Performance for the R Inc unit class in GBP, launched on 01 November 2000. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.
Past performance is not a guide to the future.
As at 31 Oct 2022. All data source LGIM unless otherwise stated. Totals may not sum due to rounding. In order to minimise transaction costs, the Fund will not always own all the assets that constitute the index and on occasion it will own assets that are not in the index. The figures shown for market capitalisation (the total share value of a company) may not be comparable between funds as they can be measured and classed in different ways.
| Health Care | 100.0 |
| Large | 87.4 | |
| Mid | 12.6 |
| Top 10 holdings | 41.4 | |
| Rest of portfolio | 58.6 |
| No. of holdings in fund | 207 |
| No. of holdings in index | 205 |
| Unitedhealth Group | 7.6 |
| Johnson & Johnson | 6.7 |
| Eli Lilly & Co | 4.4 |
| Pfizer | 3.9 |
| Abbvie | 3.8 |
| Merck & Co | 3.7 |
| Roche Holding | 3.5 |
| Thermo Fisher Scientific | 2.9 |
| Abbott Laboratories | 2.5 |
| Novo Nordisk B | 2.5 |
| United States | 72.0 | |
| Switzerland | 7.3 | |
| Japan | 4.9 | |
| United Kingdom | 4.0 | |
| Denmark | 3.4 | |
| France | 2.4 | |
| Germany | 1.9 | |
| Australia | 1.7 | |
| Korea | 0.6 | |
| Other | 1.9 |
The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.
LGIMIndex Fund Management Team
The latest dividends are shown below. The historic level of income generated by this fund may go down as well up and will vary over time.
Total dividends paid in each financial year of the fund.
A single swing price is displayed from 1st December 2020. Prior to this date, Bid and Offer prices are displayed for those funds that were previously dual priced.
The value of an investment and any income taken from it is not guaranteed and can go down as well as up, you may not get back the amount you originally invested.
Past performance is no guarantee of future results.
The return from this fund is dependent on relatively few individual investments. This means that a fall in the value of an individual investment can have a major impact on the overall performance of the fund.
Most of the fund holds investments from a particular market sector, that of health, pharmaceuticals and biotechnology. Funds like this can be more volatile than funds that invest across many market sectors. This is because the value of the fund can go up and down more often and by larger amounts than funds that are spread more widely, especially in the short term.
The fund could lose money if any institution providing services such as acting as counterparty to derivatives or other instruments, becomes unwilling or unable to meet its obligations to the fund.
Derivatives are highly sensitive to changes in the value of the asset on which they are based and can increase the size of losses and gains.
The fund may have underlying investments that are valued in currencies that are different from sterling (British pounds). Exchange rate fluctuations will impact the value of your investment. Currency hedging techniques may be applied to reduce this impact but may not entirely eliminate it.
This information is intended for investment professionals only and is for information purposes only. It should not be distributed without our permission.
No investment decisions should be made without first reviewing the key investor information document and prospectus (and any supplements thereto) of the relevant product which includes information on certain risks associated with an investment.
Unless otherwise agreed in writing, the Information on this website (a) is for information purposes only and we are not soliciting any action based on it, and (b) is not a recommendation to buy or sell securities or pursue a particular investment strategy; and (c) is not investment, legal, regulatory or tax advice. Any trading or investment decisions taken by you should be based on your own analysis and judgment (and/or that of your professional advisers) and not in reliance on us or the Information.
This information is only directed at investors resident in jurisdictions where each fund is registered for sale. It is not an offer or invitation to persons outside of those jurisdictions. We reserve the right to reject any applications from outside of such jurisdictions.
All information detailed on this website is current at the time of publication and may be changed in the future.
Source: London Stock Exchange Group plc and its group undertakings (collectively, the “LSE Group”). © LSE Group 2022. FTSE Russell is a trading name of certain of the LSE Group companies. “FTSE®” is a trade mark of the relevant LSE Group companies and is used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company’s express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.